GHRP-2

Prompts your pituitary to release a pulse of your own growth hormone rather than injecting GH itself. People run it for the same reasons as Ipamorelin — sleep, recovery, lean mass, slow recomposition — but reach for GHRP-2 when they want a stronger kick and are willing to accept the messier hormonal fingerprint that comes with it.

Its whole identity is the contrast with the “clean” Ipamorelin. GHRP-2 hits the same ghrelin receptor harder, so the GH pulse is bigger — but it also bumps prolactin and engages the stress axis (ACTH/cortisol), and it’s a noticeably stronger appetite stimulant. That hunger spike is the single most-cited practical downside, and it’s well-documented: GHRP-2 reliably makes lean and obese people eat more in controlled human studies. It also has a real clinical pedigree most peptides here lack — it’s an approved diagnostic agent for GH deficiency in Japan, given as a single test dose.

Mimics ghrelin at the GH-secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus, triggering a GH pulse and briefly suppressing somatostatin, the brake on GH release. The catch is selectivity: where Ipamorelin was engineered to hit that receptor cleanly, GHRP-2 also nudges prolactin and the ACTH/cortisol stress axis, and activates the same ghrelin appetite circuit that raises food intake. As with the rest of the class, a secretagogue triggers the pulse; a GHRH analog raises how much GH comes out per pulse — different levers, which is why they’re stacked.

The defining one is appetite — GHRP-2 is a strong ghrelin mimetic and reliably raises hunger, which is great if you’re bulking and a problem if you’re not. Beyond that it shares the GH-class effects (water retention, carpal-tunnel-type tingling, head-rush or flushing after injection, occasional lethargy), plus the off-target hormones that set it apart from Ipamorelin: measurable bumps in prolactin and in the ACTH/cortisol stress axis, both of which scale with dose. None of this rises to the theoretical cancer caution of the repair peptides — but chronically raising GH/IGF-1 isn’t free, so it’s not for anyone with active cancer concerns. As always in this unregulated market, insist on a certificate of analysis before running anything.

Run like Ipamorelin — paired with a GHRH analog (CJC-1295, with or without DAC) in a single fasted bedtime pin. The GHRH analog raises how much GH each pulse releases; GHRP-2 triggers the pulse and lifts the somatostatin brake. The combination is near-universal, and either half alone is considered half the protocol. The honest framing within the class: most people who want this profile choose the cleaner Ipamorelin and reach for GHRP-2 specifically when they want a stronger pulse (or the appetite bump) and will tolerate the prolactin/cortisol cost.